

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable recep...
Q1 2027
Aug 10, 2026
FY 2026
May 20, 2026
Q4 2026
May 20, 2026
Q3 2026
Feb 6, 2026
Q2 2026
Nov 10, 2025